Loss of exclusivity dupixent?

When does Dupixent lose exclusivity?
Dupixent (dupilumab) received FDA approval in 2017. Its primary U.S. patents, including U.S. 10,497,004, expire in 2026, while secondary patents may extend protection until 2028‑2029 [1]. In addition, the biologic 12‑year exclusivity granted by the FDA ends in 2029 [2].

What does “loss of exclusivity” actually mean?
Exclusivity ends when all patent and regulatory protections expire. At that point, other companies can develop and market biosimilar versions, provided they meet FDA’s rigorous equivalence standards. Patients and payers may see a broader range of pricing options.

Will biosimilars hit the market soon?
The earliest a biosimilar could be approved is after the last exclusive period ends—likely in 2029 or shortly after. However, some firms have already filed for biosimilar status, which can shorten the timeline if the FDA’s approval process proceeds quickly [3].

Who’s poised to enter the Dupixent space?
Regeneron/Sanofi hold the current exclusivity. Competitors such as Amgen, Pfizer, and AbbVie are monitoring the patents and may file their own biosimilar applications once the exclusivity lapses. Other biologics targeting the IL‑4/IL‑13 pathway are already on the market, but Dupixent’s dual‑indication profile gives it a competitive edge that biosimilars will seek to emulate [4].

Will prices drop once generics are allowed?
Historically, biologic pricing falls after biosimilar entry. If a biosimilar reaches the U.S. market in 2029, payers may negotiate lower reimbursement rates, potentially lowering out‑of‑pocket costs for patients with atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps.

Is there any risk of legal challenges before exclusivity ends?
Patents can be contested through litigation or invalidation proceedings. If a key patent is overturned before 2026, competitors could submit biosimilar applications earlier, though the FDA’s 12‑year exclusivity still applies for biologics, preventing immediate market entry until 2029 [5].

How does this affect patients today?
Patients who currently use Dupixent will not face immediate changes. Their prescriptions will continue to be covered under existing contracts until the exclusivity period ends. Afterward, providers may have options to switch to a biosimilar if it offers comparable efficacy and safety.

Where can I find the latest patent status?
DrugPatentWatch.com tracks Dupixent’s patent filings and expiration dates in detail. The current list of active patents and their projected expiration is available at https://drugpatentwatch.com/dupixent [1].

Sources
1. https://drugpatentwatch.com/patent/US10497004
2. FDA Biologics Exclusivity Guidance
3. FDA Biosimilar Pathway Overview
4. Industry Analyst Reports on Biologics Competition
5. USPTO Patent Litigation Database